Why Are Federal Meth Sentences Getting Longer?

While sentence lengths for most federal drug trafficking offenses have decreased in recent years, methamphetamine sentences are moving in the opposite direction, lengthening by 12% between FY2015 and FY2019. Using data from the U.S. Sentencing Commission and other sources, I consider several possible reasons for this increase. I conclude that four recent trends have jointly produced longer meth sentences: (1) drug volumes have increased, (2) the criminal history of the average offender has become more extensive, (3) weapon enhancements and charges have become more common, and (4) cases have grown increasingly likely to be sentenced as high-purity “ice” or by “actual” meth content, which carry much more punitive mandatory and guideline minimums than meth mixture. How much of the increase in sentence lengths has been attributable to shifting case characteristics (e.g., growing drug volumes, changing criminal histories, and increased weapons use) versus efforts to charge and pursue offenses that carry greater penalties? I use USSC data to conduct several simulations estimating how sentence lengths would have evolved if all meth cases were sentenced as the same meth type. I predict that the average meth trafficking sentence would have lengthened by 27–33% less, or 3.3–4.0 fewer months, if all cases were sentenced as the same meth type but all other case attributes remained unchanged. The remainder of the growth is attributable to case and offender characteristics. However, this prediction assumes that relief and leniency decisions would not change if statutory and guideline minimums were altered; to allow for this possibility, I run another set of simulations, taking these possible offsetting effects into account. My latter simulations predict that trafficking sentences might have increased 13–16% less than they did in reality, a smaller magnitude than my initial estimates. I briefly consider the underlying reasons for these trends. Some, but not all, of the changing offense characteristics may be linked to the recent shift to Mexican methamphetamine production. The timing of the shift in meth type charged suggests it may largely be the result of a change in Justice Department charging policy enacted in 2017; this shift cannot be attributed to any change in drug purity.

The impact of arrest and seizure on drug crime and harms: A systematic review

Drawing on the Global Policing Database (GPD), this review assesses the impact of supplier arrests and seizures on drug crime, drug use, drug price, drug purity, and drug harm outcomes. Just 13 impact evaluation studies (reported in 18 documents) met inclusion criteria. An evidence and gap map was constructed, showing that research to date relates primarily to drug harms, followed by drug crime and drug price, and that there are significant gaps in the impact evaluation literature. The results of this review demonstrate the limited amount of high-quality scientific evidence that can be used to examine the impact of supplier arrest and seizure on a range of drug-related outcomes.

Method development and validation of Ifetroban by RP-UPLC

The purpose of this work is to develop and validate reverse phase Ultra performance liquid chromatography (UPLC) method for the rapid and precise determination of ifetroban sodium in its pure form and in formulations. A simple, specific, accurate, precise isocratic UPLC method for analysis of Ifetroban sodium was developed and validated using a Phenomenex C18 column (50 mm x 3.0 mm, 3µ) as the stationary phase, in conjunction using Triethyl amine buffer: methanol in the proportion of 25:75 with a flow rate of 1.0 mL/min, run time is 3 min and UV detector is used at 235 nm wavelength. The developed UPLC technique was found to be rapid as the retention time was 0.56 minutes for Ifetroban peak to elute. The developed UPLC technique was validated as per the ICH guidelines for specificity, linearity, accuracy, precision, robustness and found to be satisfactory. Linearity was established in the concentration range 100-300 µg/mL with correlation coefficient of 0.998 and the equation obtained is y = 0.635x + 0.639.The percentage recovery is 100.41. The method is rugged and is trouble free and transferable. The study showed that the developed UPLC technique can be used for the estimation of drug purity, stability, solubility and with no interference of pharmaceutical excipients from the active pharmaceutical ingredient. The precision, accuracy, robustness results obtained enables rapid quantification of ifetroban for quantitative analysis.

The Emergence of Deschloro-N-ethyl-ketamine, a Ketamine Analog, in Drug Seizures and Drug Driving Cases in Hong Kong

The study reports the detection of a newly emerged drug, deschloro-N-ethyl-ketamine (2-oxo-PCE), an analog of ketamine, through forensic drug and toxicological examinations of exhibits from drug seizure cases and blood samples taken from drivers of driving under the influence of drug (DUID) cases, respectively, in Hong Kong. The submission of 2-oxo-PCE in both types of cases was firstly encountered in October 2017. A total of 31 drug seizure cases (52 items) and 4 DUID cases were found positive with 2-oxo-PCE till October 2018. Drug seizures with 2-oxo-PCE found were all in physical form (mostly in powdery or crystalline solid), resembling those samples commonly found with ketamine but having much lower purity. Although the majority of the relevant items was found with 2-oxo-PCE as the only psychoactive substance (36 items, ~69%) or as a mixture with ketamine (10 items, ~19%), other psychoactive substances including methamphetamine, methylenedioxymethamphetamine and pentylone have also been encountered (6 items, 12%). For the four DUID cases, 2-oxo-PCE and its metabolite, deschloronorketamine, were detected in all blood samples. The 2-oxo-PCE concentrations in the four blood samples were in the range of 0.08–0.31 μg/mL, being higher than the concentrations of deschloronorketamine (in the range of 0.04–0.09 μg/mL) for each sample. The 2-oxo-PCE levels found were generally lower than the ketamine levels found in reported DUID cases. With items found with 2-oxo-PCE, which were physically indistinguishable from ketamine but having lower drug purity in seizures, the lower 2-oxo-PCE blood levels with more severe impairment signs observed for the drivers in DUID cases, it is not unreasonable to speculate that users might have taken it as ketamine without knowing of its real identity and hence was adversely affected by the more potent 2-oxo-PCE.